AxoGen (AXGN) to Release Earnings on Tuesday

AxoGen (NASDAQ:AXGN) is projected to issue its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect AxoGen to post earnings of $0.08 per share and revenue of $59.8990 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:00 AM ET.

AxoGen Price Performance

AxoGen stock opened at $35.30 on Friday. The company’s 50 day simple moving average is $32.91 and its 200-day simple moving average is $24.50. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.64 and a current ratio of 4.09. AxoGen has a 1 year low of $9.22 and a 1 year high of $36.00. The company has a market capitalization of $1.63 billion, a price-to-earnings ratio of -706.00 and a beta of 1.00.

Insider Activity

In related news, Director John Johnson sold 23,693 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $31.24, for a total transaction of $740,169.32. Following the sale, the director directly owned 13,141 shares in the company, valued at approximately $410,524.84. This represents a 64.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael D. Dale sold 61,463 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $31.21, for a total transaction of $1,918,260.23. Following the completion of the sale, the chief executive officer directly owned 88,537 shares in the company, valued at approximately $2,763,239.77. This trade represents a 40.98% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 301,680 shares of company stock worth $9,174,052 over the last three months. Company insiders own 2.78% of the company’s stock.

Institutional Investors Weigh In On AxoGen

A number of large investors have recently modified their holdings of AXGN. Aquatic Capital Management LLC lifted its position in shares of AxoGen by 287.8% during the 3rd quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock worth $31,000 after purchasing an additional 1,269 shares during the last quarter. Arax Advisory Partners raised its stake in AxoGen by 362.4% in the fourth quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 819 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in AxoGen during the 4th quarter worth about $36,000. Kestra Advisory Services LLC purchased a new stake in AxoGen during the 4th quarter worth about $39,000. Finally, Tower Research Capital LLC TRC boosted its position in shares of AxoGen by 189.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,079 shares of the medical equipment provider’s stock worth $55,000 after acquiring an additional 3,327 shares in the last quarter. 80.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on AXGN shares. Wall Street Zen raised AxoGen from a “buy” rating to a “strong-buy” rating in a research report on Friday, January 23rd. Citigroup reiterated a “market outperform” rating on shares of AxoGen in a report on Thursday, October 30th. Jefferies Financial Group raised their target price on AxoGen from $29.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, December 4th. HC Wainwright lifted their target price on AxoGen from $26.00 to $39.00 and gave the company a “buy” rating in a research report on Friday, December 5th. Finally, Mizuho started coverage on shares of AxoGen in a research report on Monday, December 1st. They set an “outperform” rating and a $40.00 price target on the stock. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, AxoGen currently has an average rating of “Moderate Buy” and an average target price of $36.22.

AxoGen Company Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.